Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial.

Autor: Laursen JC; Steno Diabetes Center Copenhagen, Herlev, Denmark., Rotbain Curovic V; Steno Diabetes Center Copenhagen, Herlev, Denmark., Kroonen MYAM; Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands., Jongs N; Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands., Zobel EH; Steno Diabetes Center Copenhagen, Herlev, Denmark., Hansen TW; Steno Diabetes Center Copenhagen, Herlev, Denmark., Frimodt-Møller M; Steno Diabetes Center Copenhagen, Herlev, Denmark., Laverman GD; Ziekenhuis Groep Twente, Almelo, The Netherlands., Kooy A; Bethesda Diabetes Research Center, Hoogeveen, The Netherlands.; Department of Internal Medicine, University of Groningen, Groningen, The Netherlands., Persson F; Steno Diabetes Center Copenhagen, Herlev, Denmark., Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands., Hansen CS; Steno Diabetes Center Copenhagen, Herlev, Denmark., Rossing P; Steno Diabetes Center Copenhagen, Herlev, Denmark.; University of Copenhagen, Copenhagen, Denmark.
Jazyk: angličtina
Zdroj: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2023 Oct; Vol. 25 (10), pp. 3064-3067. Date of Electronic Publication: 2023 Jun 29.
DOI: 10.1111/dom.15180
Databáze: MEDLINE
Externí odkaz: